Patents by Inventor Deborah Palliser

Deborah Palliser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DETECTING OLIGONUCLEOTIDES
    Publication number: 20220372560
    Abstract: The present disclosure describes methods for detecting oligonucleotide presence and/or quantity in a sample.
    Type: Application
    Filed: October 29, 2020
    Publication date: November 24, 2022
    Inventors: Yinghua Shen, Dennis Keefe, Deborah Palliser
  • Aptamer-targetted antigen delivery
    Patent number: 9688991
    Abstract: A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: June 27, 2017
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Matthew Levy, Deborah Palliser, Brian Christopher Wengerter, Steven Craig Almo
  • APTAMER-TARGETTED ANTIGEN DELIVERY
    Publication number: 20150191730
    Abstract: A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 9, 2015
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Matthew Levy, Deborah Palliser, Brian Christopher Wengerter, Steven Craig Almo
  • LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY
    Publication number: 20140363493
    Abstract: The present invention addresses a need for improved vehicles for delivering small interfering RNAs (siRNAs).
    Type: Application
    Filed: June 9, 2014
    Publication date: December 11, 2014
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Deborah Palliser, Joseph Katakowski, Matthew Levy, Teresa DiLorenzo
  • siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES
    Publication number: 20120087973
    Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.
    Type: Application
    Filed: March 23, 2011
    Publication date: April 12, 2012
    Applicants: President and Fellows of Harvard College, Immune Disease Institute, Inc.
    Inventors: Judy Lieberman, Deborah Palliser, David Knipe
  • siRNA microbicides for preventing and treating diseases
    Patent number: 7943589
    Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: May 17, 2011
    Assignees: President and Fellows of Harvard College, Immune Disease Institute, Inc.
    Inventors: Judy Lieberman, Deborah Palliser, David Knipe
  • IN VIVO CTL ELICITATION BY HEAT SHOCK PROTEIN FUSION PROTEINS MAPS TO A DISCRETE DOMAIN AND IS CD4+ T CELL-INDEPENDENT
    Publication number: 20100040645
    Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual art hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.
    Type: Application
    Filed: March 9, 2009
    Publication date: February 18, 2010
    Inventors: Qian Huang, Joan F.L. Richmond, Bryan K. Cho, Deborah Palliser, Jianzhu Chen, Herman N. Eiser, Richard A. Young
  • siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES
    Publication number: 20090022783
    Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.
    Type: Application
    Filed: June 5, 2006
    Publication date: January 22, 2009
    Applicants: IMMUNE DISEASE INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Judy Lieberman, Deborah Palliser, David Knipe
  • In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
    Patent number: 6875435
    Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: April 5, 2005
    Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology
    Inventors: Qian Huang, Joan F. L. Richmond, Bryan K. Cho, Deborah Palliser, Jianzhu Chen, Herman N. Eisen, Richard A. Young
  • In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
    Publication number: 20050048079
    Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.
    Type: Application
    Filed: July 1, 2004
    Publication date: March 3, 2005
    Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology
    Inventors: Qian Huang, Joan Richmond, Bryan Cho, Deborah Palliser, Jianzhu Chen, Herman Eisen, Richard Young
  • In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
    Publication number: 20020146426
    Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.
    Type: Application
    Filed: January 16, 2001
    Publication date: October 10, 2002
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Qian Huang, Joan F.L. Richmond, Bryan K. Cho, Deborah Palliser, Jianzhu Chen, Herman N. Eisen, Richard A. Young